NASDAQ · Biotechnology

Gracell Biotechnologies Inc. (GRCL) Stock

$10.25 +0.05% NASDAQ: GRCL Healthcare

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China.

Valuation

MetricValue
Price$10.25
Market Cap$197.97M
P/E Ratio-1.55
P/B Ratio0.68
P/S Ratio0.00
EPS (TTM)$-44.85
52-Week High$10.44
52-Week Low$1.40
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-37.93%
ROA-36.68%
ROCE-43.51%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.13
Current Ratio6.78

Annual Financials (USD)

Metric20182019202020212022
Revenue$0$0$0$0$0
Operating Profit$-63.0M$-147.0M$-214.0M$-464.0M$-625.0M
Net Profit$-61.0M$-132.0M$-197.0M$-466.0M$-608.0M
EPS$-15.35$-33.35$-15.05$-35.40$-44.85
Op Margin———-126659.3%—

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$149.0M$412.0M$965.0M$2.1B$1.7B
Total Liabilities$146.0M$157.0M$145.0M$233.0M$281.0M
Cash$12.0M$312.0M$754.0M$1.8B$1.5B
Borrowings$139.0M$139.0M$103.0M$155.0M$183.0M

Latest News

Insider Activity Highlights These 3 Undervalued Small Caps In Asian Markets Simply Wall St. · May 21, 2026 GrainCorp’s Valuation After Weaker Half Year Earnings And Recent Share Price Slide Simply Wall St. · May 15, 2026 Graincorp Ltd (GRCLF) (Half Year 2026) Earnings Call Highlights: Strong Operational Performance ... GuruFocus.com · May 14, 2026 How The Story Is Shifting For GrainCorp (ASX:GNC) After The Latest Valuation Reset Simply Wall St. · May 4, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-62.0M$-135.0M$-198.0M$-305.0M$-3.3B
Investing Cash Flow$-125.0M$-15.0M$-173.0M$-98.0M$-663.0M
Financing Cash Flow$139.0M$350.0M$756.0M$1.5B$228.0M
Net Cash Flow$-37.0M$300.0M$442.0M$1.1B$-2.6B
Free Cash Flow$-73.0M$-192.0M$-278.0M$-361.0M$-3.6B

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-0.12
FCF Yield-271.40%
Quick Ratio6.78
Interest Coverage-92.72
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.

Gracell Biotechnologies Inc. is headquartered in CN.

Gracell Biotechnologies Inc. (GRCL) stock trades at $10.25 with a market capitalization of $197.97M. The stock is valued at a price-to-earnings (P/E) ratio of -1.55, price-to-book of 0.68, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.40 and $10.44, and currently trades 1.8% below its 52-week high.

On profitability, Gracell Biotechnologies Inc. generates a return on equity (ROE) of -37.93%, return on capital employed of -43.51%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.gracellbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides